AVTR Avantor, Inc.
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Avantor (NYSE: AVTR)
›
Avantor (NYSE: AVTR) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 13,500 employees.
The shares were at 15.07 USD on 20 November 2026, up 32.9% over 52 weeks. Its 52-week range is 7.265 USD to 17.45 USD: the price is 13.6% below the high and 107.5% above the low.
At a market capitalisation of 10.25B USD, it trades at 30.2 times trailing earnings and 17.0 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 39% for AVTR.
Avantor reports return on equity of -9.5%, an operating margin of 8.0% and revenue up 4.6% year over year.
Its debt exceeds its cash by 3.22B USD, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 13 analysts cover the stock; their mean price target of 17.35 USD is 15.1% above the current price. The next earnings report is expected on 10 February 2027.